{'fraction_non_alphanumeric': 0.017297297297297298, 'fraction_numerical': 0.014054054054054054, 'mean_word_length': 5.342465753424658, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Actinomycin D Revisited in Testicular Cancer. A Case Report

Background Between 20–30% of patients with advanced germ cell tumors relapse or fail to achieve a complete response to conventional cisplatin based chemotherapy. Ifosphamide has been used very effectively in combination with cisplatin and etoposide (VIP) or in combination with cisplatin and vinblastine (VeIP). Actinomycin D with chlorambucil and methotrexate was widely used in the 1960s with complete responses in 20% of patients and long term survival of 6–10%. There exists no information on the use of actinomycin as a salvage in cisplatin refractory patients. Methods and Results One patient with metastatic germ cell tumor who failed chemotherapy with cisplatin and ifosphamide was successfully treated with an actinomycin D based regimen. Conclusions Actinomycin D is an active agent in testicular cancer and maybe used in patients refractory to platinum.